| 1.23 -0.01 (-0.81%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.58 | 1-year : | 1.85 |
| Resists | First : | 1.36 | Second : | 1.58 |
| Pivot price | 1.23 |
|||
| Supports | First : | 0.97 |
Second : | 0.74 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.16 |
| MA(100) : | 1.19  |
MA(250) : | 1.2 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 67.6 |
D(3) : | 75.6 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 3.82 | Low : | 0.22 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CGTX ] has closed above bottom band by 50.0%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.27 - 1.28 | 1.28 - 1.29 |
| Low: | 1.15 - 1.16 | 1.16 - 1.17 |
| Close: | 1.22 - 1.23 | 1.23 - 1.24 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Mon, 04 May 2026
Cognition Therapeutics (NASDAQ: CGTX) CFO has 8,567 shares withheld for taxes - Stock Titan
Mon, 27 Apr 2026
[ARS] COGNITION THERAPEUTICS INC SEC Filing - Stock Titan
Tue, 07 Apr 2026
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative
Tue, 31 Mar 2026
Cognition Therapeutics CEO Issues Letter to Shareholders - GlobeNewswire
Thu, 26 Mar 2026
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update - Yahoo Finance
Thu, 26 Mar 2026
No approved DLB psychosis drugs; Cognition maps FDA path for one - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 89 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 23.5 (%) |
| Shares Short | 7,320 (K) |
| Shares Short P.Month | 7,000 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76 % |
| Return on Equity (ttm) | -88.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -3.85 |
| PEG Ratio | 0 |
| Price to Book value | 3.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|